Clinical consequences of the polymorphism of azathioprine metabolism

Transplantation Proceedings

Volumn 32, Issue 8, 2000, Pages 2780-

  Thervet, E ^a,b   Anglicheau, D ^a,b   Toledano, N ^b   Kreis, H ^c   Legendre, Ch ^a   Beaune, P ^b  

^a SAINT LOUIS HOSPITAL   (France)

^b INSERM   (France)

^c HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; MERCAPTOPURINE; THIOPURINE METHYLTRANSFERASE; TIOGUANINE;

CHEMICAL MODIFICATION; CLINICAL ARTICLE; CONFERENCE PAPER; DRUG METABOLISM; ENZYME ACTIVITY; ENZYME INDUCTION; GENETIC POLYMORPHISM; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY BIOPSY; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; PRIORITY JOURNAL;

AZATHIOPRINE; CYCLOSPORINE; DRUG THERAPY, COMBINATION; ERYTHROCYTES; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; METHYLTRANSFERASES; POLYMORPHISM, GENETIC; POSTOPERATIVE PERIOD; PROSPECTIVE STUDIES;

EID: 0034530621     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0041-1345(00)01882-0     Document Type: Conference Paper

References (2)

1. Mircheva J, Legendre C, Soria-Royer C, et al: Transplantation 60:639, 1995
2. El-Yazigi A, Abdel Wahab F: Ther Drug Monit 14:312, 1992